Anti-laminin-332 mucous membrane pemphigoid associated with recurrent metastatic prostate carcinoma: Hypothesis for a paraneoplastic phenomenon

European Journal of Dermatology

Volumn 21, Issue 3, 2011, Pages 401-404

  Young, Alexis L ^a   Bailey, Elizabeth E ^a   Colaço, Shanthi M ^a   Engler, Danielle E ^a   Grossman, Marc E ^a  

^a Department of Medicine   (United States)

Author keywords

Anti laminin 332 mucous membrane pemphigoid; Autoimmune blistering disease; Prostate carcinoma

Indexed keywords

COMPLEMENT COMPONENT C3; DAPSONE; DOCETAXEL; IMMUNOGLOBULIN G; KALININ ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CASE REPORT; COMPLEMENT DEPOSITION; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN DEPOSITION; MALE; METASTASIS; MOUTH ULCER; MUCOUS MEMBRANE PEMPHIGOID; ORAL BIOPSY; ORCHIECTOMY; PROSTATE ADENOCARCINOMA; RECURRENT CANCER; SORE THROAT; SYMBLEPHARON; WEIGHT REDUCTION;

ANTIBODIES, NEOPLASM; AUTOANTIBODIES; CELL ADHESION MOLECULES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PARANEOPLASTIC SYNDROMES; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 79960821074     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1360     Document Type: Article

References (25)

1. Durbeej M. Laminins. Cell Tissue Res 339: 259-268.
2. Sadler E, Lazarova Z, Sarasombath P, et al. A widening perspective regarding the relationship between anti-epiligrin cicatricial pemphigoid and cancer. J Dermatol Sci 2007; 47: 1-7.
3. Tzu J, Marinkovich MP. Bridging structure with function: structural, regulatory, and developmental role of laminins. Int J Biochem Cell Biol 2008; 40: 199-214.
4. Bauer J, Schumann H, Sonnichsen K, et al. Molecular diagnostics facilitate distinction between lethal and non-lethal subtypes of junctional epidermolysis bullosa: a case report and review of the literature. Eur J Pediatr 2002; 161: 672-9.
5. Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. Medicine (Baltimore) 2003; 82: 177-86.
6. Setterfield J, Shirlaw PJ, Kerr-Muir M, et al. Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. Br J Dermatol 1998; 138: 602-10.
7. Egan CA, Yancey KB. The clinical and immunopathological manifestations of anti-epiligrin cicatricial pemphigoid, a recently defined subepithelial autoimmune blistering disease. Eur J Dermatol 2000; 10: 585-9.
8. Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357: 1850-1.
9. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100.
10. Chow WH, Gridley G, Mellemkjaer L, et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995; 6: 9-13.
11. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134: 1087-95.
12. Fukushima S, Egawa K, Nishi H, et al. Two cases of anti-epiligrin cicatricial pemphigoid with and without associated malignancy. Acta Derm Venereol 2008; 88: 484-7.
13. Kariya Y, Gu J. Roles of laminin-332 and alpha6beta4 integrin in tumor progression. Mini Rev Med Chem 2009; 9: 1284-91.
14. Miyazaki K. Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion. Cancer Sci 2006; 97: 91-8.
15. Hao J, Jackson L, Calaluce R, et al. Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer. Am J Pathol 2001; 158: 1129-35.
16. Tripathi M, Nandana S, Yamashita H, et al. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem 2008; 283: 30576-84.
17. Chamberlain AJ, Cooper SM, Allen J, et al. Paraneoplastic immunobullous disease with an epidermolysis bullosa acquisita phenotype: two cases demonstrating remission with treatment of gynaecological malignancy. Australas J Dermatol 2004; 45: 136-9.
18. Taniuchi K, Takata M, Matsui C, et al. Antiepiligrin (laminin 5) cicatricial pemphigoid associated with an underlying gastric carcinoma producing laminin 5. Br J Dermatol 1999; 140: 696-700.
19. Setterfield J, Shirlaw PJ, Lazarova Z, et al. Paraneoplastic cicatricial pemphigoid. Br J Dermatol 1999; 141: 127-31.
20. Yeh SW, Ahmed B, Sami N, et al. Blistering disorders: diagnosis and treatment. Dermatol Ther 2003; 16: 214-23.
21. Thorne JE, Woreta FA, Jabs DA, et al. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology 2008; 115: 2146-2152 e1.
22. Leverkus M, Schmidt E, Lazarova Z, et al. Antiepiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring autoimmune subepidermal bullous diseases? Arch Dermatol 1999; 135: 1091-8.
23. Shannon JF, Mackenzie-Wood A, Wood G, et al. Cicatricial pemphigoid in non-Hodgkin's lymphoma. Intern Med J 2003; 33: 396-7.
24. Matsushima S, Horiguchi Y, Honda T, et al. A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: review of Japanese cases and evaluation of risk for internal malignancy. J Dermatol 2004; 31: 10-5.
25. Abe M, Koizumi H, Matsumura K, et al. Cicatricial pemphigoid associated with lung tumor. Jpn J Clin Dermatol 2000; 54: 685-8.